Advanced search
1 file | 273.57 KB

Clinical implications of measurable residual disease in AML : review of current evidence

Author
Organization
Abstract
Despite the fact that 80% of adult acute myeloid leukaemia patients reach complete morphological remission after induction chemotherapy, many of them relapse. Many studies have shown that detection of minimal residual disease (defined as 'any detectable evidence of persistent leukaemic cells during complete morphological remission') has an added value in prediction of relapse and survival, and is more than just a surrogate marker for already known risk factors in AML. As such, the behaviour of the disease during treatment might become equally or even more important to decide whether or not an upgrade of treatment (such as an allogeneic stem cell transplantation) is necessary to improve outcome. However, there are still many open issues as to what the ideal time point is to measure MRD, which threshold is clinically significant, what sample (peripheral blood or bone marrow) should be used and how we can standardize tests so that results from different labs become comparable. This review gives an overview of currently available evidence regarding technical issues, prognostic impact and MRD-directed treatment in AML.
Keywords
Measurable or minimal residual disease, Acute myeloid leukaemia, Flow cytometry, Next generation sequencing, Prognosis, MRD-directed treatment, ACUTE MYELOID-LEUKEMIA, 1ST COMPLETE REMISSION, RISK STRATIFICATION, INDUCTION THERAPY, PROGNOSTIC IMPACT, PERIPHERAL-BLOOD, FLOW-CYTOMETRY, RQ-PCR, MUTATIONS, T(8/21)

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 273.57 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Moors, Ine, Karl Vandepoele, Jan Philippé, Dries Deeren, Dominik Selleslag, Dimitri Breems, Nicole Straetmans, Tessa Kerre, and Barbara Denys. 2019. “Clinical Implications of Measurable Residual Disease in AML : Review of Current Evidence.” Critical Reviews in Oncology Hematology 133: 142–148.
APA
Moors, I., Vandepoele, K., Philippé, J., Deeren, D., Selleslag, D., Breems, D., Straetmans, N., et al. (2019). Clinical implications of measurable residual disease in AML : review of current evidence. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 133, 142–148.
Vancouver
1.
Moors I, Vandepoele K, Philippé J, Deeren D, Selleslag D, Breems D, et al. Clinical implications of measurable residual disease in AML : review of current evidence. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2019;133:142–8.
MLA
Moors, Ine et al. “Clinical Implications of Measurable Residual Disease in AML : Review of Current Evidence.” CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 133 (2019): 142–148. Print.
@article{8618797,
  abstract     = {Despite the fact that 80% of adult acute myeloid leukaemia patients reach complete morphological remission after induction chemotherapy, many of them relapse. Many studies have shown that detection of minimal residual disease (defined as 'any detectable evidence of persistent leukaemic cells during complete morphological remission') has an added value in prediction of relapse and survival, and is more than just a surrogate marker for already known risk factors in AML. As such, the behaviour of the disease during treatment might become equally or even more important to decide whether or not an upgrade of treatment (such as an allogeneic stem cell transplantation) is necessary to improve outcome. However, there are still many open issues as to what the ideal time point is to measure MRD, which threshold is clinically significant, what sample (peripheral blood or bone marrow) should be used and how we can standardize tests so that results from different labs become comparable. This review gives an overview of currently available evidence regarding technical issues, prognostic impact and MRD-directed treatment in AML.},
  author       = {Moors, Ine and Vandepoele, Karl and Philippé, Jan and Deeren, Dries and Selleslag, Dominik and Breems, Dimitri and Straetmans, Nicole and Kerre, Tessa and Denys, Barbara},
  issn         = {1040-8428},
  journal      = {CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY},
  keywords     = {Measurable or minimal residual disease,Acute myeloid leukaemia,Flow cytometry,Next generation sequencing,Prognosis,MRD-directed treatment,ACUTE MYELOID-LEUKEMIA,1ST COMPLETE REMISSION,RISK STRATIFICATION,INDUCTION THERAPY,PROGNOSTIC IMPACT,PERIPHERAL-BLOOD,FLOW-CYTOMETRY,RQ-PCR,MUTATIONS,T(8/21)},
  language     = {eng},
  pages        = {142--148},
  title        = {Clinical implications of measurable residual disease in AML : review of current evidence},
  url          = {http://dx.doi.org/10.1016/j.critrevonc.2018.11.010},
  volume       = {133},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: